ImmunoGen, Inc.
IMGN
Hisse Senetlerindeki Sıralama
#2903
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Hisse Fiyatı
$31.23
Son senkronizasyon: 2024-02-13
Piyasa Değeri
$6.24B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret ImmunoGen, Inc. (IMGN)
Kategori
Healthcare
ImmunoGen, Inc. (IMGN) için kazanç
2026 itibarıyla kazanç TTM: 0
ImmunoGen, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
ImmunoGen, Inc. için kazanç geçmişi 2002 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2022 | $-221.71M | 59.16% |
| 2021 | $-139.30M | 213.94% |
| 2020 | $-44.37M | -57.39% |
| 2019 | $-104.13M | -37.97% |
| 2018 | $-167.87M | 74.85% |
| 2017 | $-96.01M | -38.74% |
| 2016 | $-156.73M | 158.04% |
| 2015 | $-60.74M | -14.89% |
| 2014 | $-71.36M | -1.99% |
| 2013 | $-72.81M | -0.69% |
| 2012 | $-73.32M | 25.82% |
| 2011 | $-58.27M | 13.87% |
| 2010 | $-51.18M | 59.74% |
| 2009 | $-32.04M | 0.14% |
| 2008 | $-31.99M | 68.80% |
| 2007 | $-18.95M | 6.38% |
| 2006 | $-17.82M | 63.13% |
| 2005 | $-10.92M | 86.01% |
| 2004 | $-5.87M | -70.56% |
| 2003 | $-19.95M | 37.55% |
| 2002 | $-14.50M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
